New biosensors aim to diagnose infections in minutes

NCT ID NCT06548841

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 2 times

Summary

This study tested two new types of biosensor platforms to detect viruses, bacteria, and parasites in blood and respiratory samples. The goal was to see if these devices could be accurate, fast, and cheap alternatives to standard lab tests. Researchers enrolled 149 adults with or without SARS-CoV-2, Pseudomonas aeruginosa, or Leishmania infantum infections.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
Nanobiotechnology platforms (biosensors using molecular probes or bacteriophages)
What this could lead to
If successful, these biosensors could provide fast, low-cost diagnosis for infections like COVID-19, Pseudomonas, and Leishmania, especially in low-resource settings.
What could go wrong
This is a completed early-stage feasibility study with 149 participants. The results may not confirm real-world accuracy, and the technology may not be scalable or reliable across different settings.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for INFECTION VIRAL are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Department of Medical and Surgical Sciences, University of Bologna

    Bologna, Bologna, 40138, Italy

More trials for these conditions

Other studies related to the condition(s) this trial covers.